李之凡;吴娜琼;

• 1:中国医学科学院北京协和医学院阜外医院国家心血管病中心心血管代谢中心

摘要(Abstract)：

动脉粥样硬化性泛血管疾病是指两个或两个以上动脉血管床发生动脉粥样硬化。近年来,从泛血管的角度系统认识血管性疾病并制订诊治策略逐渐受到重视。血脂异常作为动脉粥样硬化的危险因素,对动脉粥样硬化性泛血管疾病的发生、进展、严重程度及预后有不同程度的影响。更积极的降脂疗法对于泛血管疾病患者效果更佳、意义更深远。本文就动脉粥样硬化性泛血管疾病的发生风险与血脂异常的关系及泛血管疾病血脂管理现状和策略,对近年研究进展作一综述。

关键词(KeyWords)： 泛血管疾病;血脂异常;动脉粥样硬化

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 李之凡;吴娜琼;

参考文献(References)：

• [1]GUTIERREZ J A,ADAY A W,PATEL M R,et al.Polyvascular Disease:Reappraisal of the Current Clinical Landscape[J].Circ Cardiovasc Interv,2019,12(12):e007385.
• [2]MEIZELS A,ZEITOUN D M,BATAILLE V,et al.Impact of polyvascular disease on baseline characteristics,management and mortality in acute myocardial infarction.The Alliance project[J].Arch Cardiovasc Dis,2010,103(4):207-214.
• [3]VLAJINAC H D,MARINKOVI?J M,MAKSIMOVI?M Z,et al.The prevalence of polyvascular disease in patients with carotid artery disease and peripheral artery disease[J].Kardiol Pol,2019,77(10):926-934.
• [4]MATTINA A,GIAMMANCO A,GIRAL P,et al.Polyvascular subclinical atherosclerosis in familial hypercholesterolemia:The role of cholesterol burden and gender[J].Nutr Metab Cardiovasc Dis,2019,29(10):1068-1076.
• [5]CONROY R M,PY?R?L?K,FITZGERALD A P,et al.Estimation of ten-year risk of fatal cardiovascular disease in Europe:the SCORE project[J].Eur Heart J,2003,24(11):987-1003.
• [6]D'AGOSTINO R B,VASAN R S,PENCINA M J,et al.General cardiovascular risk profile for use in primary care:the Framingham Heart Study[J].Circulation,2008,117(6):743-753.
• [7]PIEPOLI M F,HOES A W,AGEWALL S,et al.2016European Guidelines on cardiovascular disease prevention in clinical practice:The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention&Rehabilitation (EACPR)[J].Eur Heart J,2016,37(29):2315-2381.
• [8]MENDIS S,LINDHOLM L H,MANCIA G,et al.World Health Organization (WHO) and International Society of Hyper tension (ISH) risk prediction charts:assessment of cardiov ascular risk for prevention and control of cardiovascular disease in low and middle-income countries[J].J Hyperten,2007,25(8):1578-1582.
• [9]WHO CVD Risk Chart Working Group.World Health Organization cardiovascular disease risk charts:revised models to estimate risk in 21 global regions[J].Lancet Glob Health,2019,7(10):e1332-e1345.
• [10]HIPPISLEY-COX J,COUPLAND C,VINOGRADOVA Y,et al.Predicting cardiovascular risk in England and Wales:prospective derivation and validation of QRISK2[J].BMJ,2008,336(7659):1475-1482.
• [11]H I P P I S L E Y-C O X J,C O U P L A N D C,B R I N D L E P.Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease:prospective cohort study[J].BMJ,2017,357:j2099.
• [12]HAJIFATHALIAN K,UEDA P,LU Y,et al.A novel risk score to predict cardiovascular disease risk in national populations (Globorisk):a pooled analysis of prospective cohorts and health examination surveys[J].Lancet Diabetes Endocrinol,2015,3(5):339-355.
• [13]YANG X,LI J,HU D,et al.Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population:The China-PAR Project (Prediction for ASCVD Risk in China)[J].Circulation,2016,134(19):1430-1440.
• [14]中国成人血脂异常防治指南修订联合委员会．中国成人血脂异常防治指南（2016年修订版）[J]．中国循环杂志，2016,31(10):937-953．
• [15]ASSMANN G,CULLEN P,SCHULTE H.Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster(PROCAM) study[J].Circulation,2002,105(3):310-315.
• [16]FERRARIO M,CHIODINI P,CHAMBLESS L E,et al.Prediction of coronary events in a low incidence population.Assessing accuracy of the CUORE Cohort Study prediction equation[J].Int J Epidemiol,2005,34(2):413-421.
• [17]WOODWARD M,BRINDLE P,TUNSTALL-PEDOE H,et al.Adding social deprivation and family history to cardiovascular risk assessment:the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC)[J].Heart,2007,93(2):172-176.
• [18]RIDKER P M,BURING J E,RIFAI N,et al.Development and validation of improved algorithms for the assessment of global cardiovascular risk in women:the Reynolds Risk Score[J].JAMA,2007,297(6):611-619.
• [19]RIDKER P M,PAYNTER N P,RIFAI N,et al.C-reactive protein and parental history improve global cardiovascular risk prediction:the Reynolds Risk Score for men[J].Circulation,2008,118(22):2243-2251.
• [20]GOFF D C,LLOYD-JONES D M,BENNETT G,et al.2013ACC/AHA guideline on the assessment of cardiovascular risk:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation,2014,129(25 Suppl 2):S49-S73.
• [21]JUKEMA J W,SZAREK M,ZIJLSTRA L E,et al.Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome:ODYSSEY OUTCOMES Trial[J].J Am Coll Cardiol,2019,74(9):1167-1176.
• [22]SONG P,SEOK J M,KIM W S,et al.Increased lipoprotein(a)is associated with polyvascular disease in patients undergoing coronary artery bypass graft[J].Atherosclerosis,2011,219(1):285-290.
• [23]AFANASIEVA O I,TMOYAN N A,KLESAREVA E A,et al.The Relationship of the Concentration of Lipoprotein(a) and Markers of Inflammation with Multifocal Atherosclerosis in Women[J].Kardiologiia,2019,59(10):39-48.
• [24]TMOYAN N A,AFANASIEVA O I,EZHOV M V,et al.Lipoprotein(a),Immunity,and Inflammation in Polyvascular Atherosclerotic Disease[J].J Cardiovasc Dev Dis,2021,8(2):11.
• [25]ADAY A W,LAWLER P R,COOK N R,et al.Lipoprotein Particle Profiles,Standard Lipids,and Peripheral Artery Disease Incidence[J].Circulation,2018,138(21):2330-2341.
• [26]VAN DEN BERG M J,VAN DER GRAAF Y,DE BORST G J,et al.Low-Density Lipoprotein Cholesterol,Non-High-Density Lipoprotein Cholesterol,Triglycerides,and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease[J].Am J Cardiol,2016,118(6):804-810.
• [27]BORéN J,CHAPMAN M J,KRAUSS R M,et al.Lowdensity lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus statement from the European Atherosclerosis Society Consensus Panel[J].Eur Heart J,2020,41(24):2313-2330.
• [28]AMARENCO P,KIM J S,LABREUCHE J,et al.A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke[J].N Engl J Med,2020,382(1):9.
• [29]CORRADO E,MIGNANO A,COPPOLA G.Use of statins in patients with peripheral artery disease[J].Trends Cardiovasc Med,2020,30(5):257-262.
• [30]SABATINE M S,GIUGLIANO R P,KEECH A C,et al.Evolo cumab and Clinical Outcomes in Patients with Cardio vascular Disease[J].N Engl J Med,2017,376(18):1713-1722.
• [31]SCHWARTZ G G,STEG P G,SZAREK M,et al.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome[J].N Engl J Med,2018,379(22):2097-2107.
• [32]BERGER J S,LADAPO J A.Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease[J].J Am Coll Cardiol,2017,69(18):2293-2300.
• [33]RICCO J B.Why have cardiovascular events in peripheral arterial disease patients failed to decline:lessons from a 10-year registry[J].Eur Heart J Qual Care Clin Outcomes,2019,5(4):279-280.
• [34]SARTIPY F,LUNDIN F,WAHLBERG E,et al.Cardiovascular long-term outcome and prophylactic treatment patterns in peripheral arterial disease in a population-based cohort[J].Eur Heart J Qual Care Clin Outcomes,2019,5(4):310-320.
• [35]FROEHLICH J B,MUKHERJEE D,AVEZUM A,et al.Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes.The Global Registry of Acute Coronary Events (GRACE)[J].Am Heart J,2006,151(5):1123-1128.
• [36]ABOYANS V,RICCO J B,BARTELINK M E L,et al.2017ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases,in collaboration with the European Society for Vascular Surgery (ESVS):Document covering atherosclerotic disease of extracranial carotid and vertebral,mesenteric,renal,upper and lower extremity arteriesEndorsed by:the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)[J].Eur Heart J,2018,39(9):763-816.
• [37]VOLIS I,SALIBA W,JAFFE R,et al.Effect of Cerebrovascular and/or Peripheral Artery Disease With or Without Attainment of Lipid Goals on Long-Term Outcomes in Patients With Coronary Artery Disease[J].Am J Cardiol,2020,128:28-34.
• [38]BONACA M P,GUTIERREZ J A,CANNON C,et al.Polyvascular disease,type 2 diabetes,and long-term vascular risk:a secondary analysis of the IMPROVE-IT trial[J].Lancet Diabetes Endocrinol,2018,6(12):934-943.
• [39]VALLEJO-VAZ A J,RAY K K,GINSBERG H N,et al.Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients:Pooled analysis of nine ODYSSEY trials of alirocumab versus control[J].Atherosclerosis,2019,288:85-93.
• [40]JASHARI F,IBRAHIMI P,NICOLL R,et al.Coronary and carotid atherosclerosis:similarities and differences[J].Atherosclerosis,2013,227(2):193-200.
• [41]FOWKES F G,RUDAN D,RUDAN I,et al.Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010:a systematic review and analysis[J].Lancet,2013,382(9901):1329-1340.
• [42]SIGALA F,OIKONOMOU E,ANTONOPOULOS A S,et al.Coronary versus carotid artery plaques.Similarities and differences regarding biomarkers morphology and prognosis[J].Curr Opin Pharmacol,2018,39:9-18.
• [43]LIANG Y,YAN Z,SUN B,et al.Cardiovascular risk factor profiles for peripheral artery disease and carotid atherosclerosis among Chinese older people:a population-based study[J].PloSone,2014,9(1):e85927.
• [44]HOSHINO H,ITOH Y,YAMADA S,et al.Prevalence and clinical features of asymptomatic peripheral artery disease in Japanese stroke patients[J].J Stroke Cerebrovasc Dis,2013,22(3):255-259.
• [45]KIM H,KIM J Y,MIN P K,et al.Outcomes and Associated Factors of Discrepant Coronary and Carotid Atherosclerosis[J].Int Heart J,2020,61(6):1142-1149.
• [46]FALK E,SHAH P K,FUSTER V.Coronary plaque disruption[J].Circulation,1995,92(3):657-671.
• [47]DERKSEN W J,DE VRIES J P,VINK A,et al.Histologic atherosclerotic plaque characteristics are associated with restenosis rates after endarterectomy of the common and superficial femoral arteries[J].J Vasc Surg,2010,52(3):592-599.
• [48]TSAI S,VEGA G L.Coronary and peripheral artery plaques:do differences in plaque characteristics translate to differences in lipid management?[J].J Investig Med,2020,68(6):1141-1151.
• [49]SILVERMAN M G,FERENCE B A,IM K,et al.Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions:A Systematic Review and Meta-analysis[J].JAMA,2016,316(12):1289-1297.
• [50]RAMOS R,GARCíA-GIL M,COMAS-CUFíM,et al.Statins for Prevention of Cardiovascular Events in a LowRisk Population With Low Ankle Brachial Index[J].J Am Coll Cardiol,2016,67(6):630-640.
• [51]Heart Protection Study Collaborative Group.Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in20,536 people with peripheral arterial disease and other highrisk conditions[J].J Vasc Surg,2007,45(4):645-654.
• [52]KUMBHANI D J,STEG P G,CANNON C P,et al.Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease:insights from the REACH registry[J].Eur Heart J,2014,35(41):2864-2872.
• [53]ARYA S,KHAKHARIA A,BINNEY Z O,et al.Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease[J].Circulation,2018,137(14):1435-1446.
• [54]WEST A M,ANDERSON J D,MEYER C H,et al.The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline[J].Atherosclerosis,2011,218(1):156-162.
• [55]BRUNNER G,YANG E Y,KUMAR A,et al.The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)[J].Atherosclerosis,2013,231(2):371-377.
• [56]BONACA M P,NAULT P,GIUGLIANO R P,et al.LowDensity Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease:Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)[J].Circulation,2018,137(4):338-350.
• [57]RIZZO M,PERNICE V,FRASHERI A,et al.Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease[J].Atherosclerosis,2008,197(1):237-241.
• [58]CHMIEL J,KSI??EK M K,STRYSZAK W,et al.Temporal changes in the pattern of invasive angiography use and its outcome in suspected coronary artery disease:implications for patient management and healthcare resources utilization[J].Postepy Kardiol Interwencyjnej,2018,14(3):247-257.
• [59]CHAN A W.Expanding roles of the cardiovascular specialists in panvascular disease prevention and treatment[J].Can JCardiol,2004,20(5):535-544.
• [60]HOLMES D R J R,HOPKINS L N.Interventional Cardiology and Acute Stroke Care Going Forward:JACC Review Topic of the Week[J].J Am Coll Cardiol,2019,73(12):1483-1490.
• [61]POWERS W J,RABINSTEIN A A,ACKERSON T,et al.2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J].Stroke,2018,49(3):e46-e110.